{"filings":[{"id":730679,"accession_number":"0001193125-26-245636","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2026-05-28T22:12:37+00:00","items":["5.07"],"status":"ready","headline":"Rani Therapeutics shareholders elect all 7 directors, ratify auditor at 2026 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All director nominees elected with >57M votes each; Jean-Luc Butel had highest withhold (4,997,042).","Ratification of CBIZ CPAs as auditor for FY2026 passed with 77,019,828 for, 332,645 against, 54,190 abstain.","Record date had 99,812,515 Class A and 23,970,359 Class B shares outstanding, voting together as a single class."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":676801,"accession_number":"0001193125-26-239977","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2026-05-27T00:41:33+00:00","items":["8.01","9.01"],"status":"ready","headline":"Rani Therapeutics raises $20M via common stock and pre-funded warrant offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issues 12.48M shares at $1.07/share and pre-funded warrants for 6.21M shares at $1.0699.","Gross proceeds of ~$20M; closing expected May 27, 2026.","Placement agents: H.C. Wainwright & Co. and Chardan Capital Markets; lock-up agreements for 60 days.","Offering made under effective S-3 registration statement filed August 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":470798,"accession_number":"0001193125-26-226691","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2026-05-15T20:08:23+00:00","items":["2.02","3.01","5.02","9.01"],"status":"ready","headline":"Rani Therapeutics Q1 net loss narrows to $8M; Nasdaq bid price non-compliance; CFO to depart","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net loss $8.0M, narrowed from $12.7M YoY; cash $43.4M expected to fund operations into Q4 2027.","Received Nasdaq deficiency notice for bid price below $1.00; 180-day cure period until Nov 9, 2026.","CFO Svai Sanford to resign after successor appointed; separation includes 9 months salary ($491,400) and accelerated vesting.","Phase 1 study of oral GLP-1/GLP-2 dual agonist RT-114 ongoing in obesity; partnered with ProGen.","Appointed new CTO, Head of Strategy, and Strategic Advisor in Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110096,"accession_number":"0001193125-26-126240","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rani Therapeutics reports Q4 net loss of $9.1M; announces up to $1.085B Chugai collaboration and $60.3M placement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Collaboration with Chugai for up to $1.085B to develop oral therapy using RaniPill; Chugai may expand to 5 additional targets.","Raised $60.3M via oversubscribed private placement led by Samsara BioCapital, including $6.0M debt conversion.","Initiated Phase 1 study of RT-114 (oral GLP-1/GLP-2 dual agonist) via RaniPill for obesity in December 2025.","Cash and equivalents $49.7M as of Dec 31, 2025; expected to fund operations into Q4 2027, including Chugai milestone.","Net loss for FY2025 was $41.0M, narrowed from $56.6M in FY2024; R&D expenses decreased 24% to $20.2M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110095,"accession_number":"0001193125-26-001098","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2026-01-02T23:59:59+00:00","items":["1.02","3.03","5.03","5.07","9.01"],"status":"ready","headline":"Rani Therapeutics terminates TRA, adopts governance changes reducing Class B voting to 1 vote","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated Tax Receivable Agreement with InCube Labs; no payments or early termination fees required.","Amended charter reduces Class B common stock voting power from 10 to 1 vote per share.","Eliminated stockholder written consent, classified board; added supermajority vote to amend bylaws.","Changes approved by majority holder written consent on Nov 24, 2025; effective Dec 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126656,"accession_number":"0001193125-25-269722","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rani Therapeutics reports Q3 2025 results, announces $1.085B Chugai collaboration and $60.3M financing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered collaboration with Chugai for oral therapy using RaniPill platform; potential total value up to $1.085B including options for up to five additional targets.","Closed $60.3M oversubscribed private placement led by Samsara BioCapital with participation from RA Capital, Anomaly, Special Situations Funds, and Invus.","Appointed Abraham Bassan (Samsara BioCapital) and Vasudev Bailey, Ph.D. (Anomaly Ventures) to the Board of Directors.","Cash runway expected into 2028; Phase 1 trial of oral obesity therapy RT-114 planned by end of 2025.","Net loss for Q3 2025 was $7.9M, improved from $12.7M in prior year period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126655,"accession_number":"0001193125-25-250614","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2025-10-27T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"Rani Therapeutics closes private placement of 42.6M shares and warrants; board changes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed private placement of 42,633,337 shares of Class A common stock, warrants to purchase 125,000,004 shares, and pre-funded warrants for 82,366,667 shares.","Post-closing shares outstanding: 97,541,221.","Directors Andrew Farquharson and Maulik Nanavaty resigned effective closing; no disagreement cited.","Abraham Bassan (Samsara BioCapital) and Vasudev Bailey (Anomaly Ventures) appointed as directors.","Samsara and Anomaly each have board designation rights while holding at least 25% of securities issued."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126654,"accession_number":"0001193125-25-241963","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2025-10-17T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Rani raises $60.3M, partners with Chugai on hemophilia drug via RaniPill","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement: ~$60.3M gross from 42.6M shares and warrants at $0.48/share (institutional) and $0.605 (affiliate).","Loan amendment: Avenue converts $6M debt into 12.5M shares and warrants on same PIPE terms.","Collaboration with Chugai: $10M upfront, up to $18M tech transfer, $57M development, $100M sales milestones, plus royalties.","Samsara and Anomaly get board appointment rights if each holds ≥25% of its PIPE securities.","Warrants exercisable five years post-stockholder approval; pre-funded warrants exercisable immediately."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143427,"accession_number":"0000950170-25-104998","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rani Therapeutics Q2 net loss $11.2M, cash at $10.2M; collaboration with Chugai announced","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $11.2M for Q2 2025 vs $13.4M in Q2 2024; includes $3.3M stock-based compensation.","Cash, equivalents and marketable securities fell to $10.2M as of June 30, 2025 from $27.6M at Dec 31, 2024.","Entered research collaboration with Chugai for two undisclosed molecules; bioequivalence to subcutaneous delivery confirmed.","Warrant inducement transaction yielded $4.3M gross proceeds; registered direct offering raised $3.0M.","Phase 1 trial of oral GLP-1/GLP-2 agonist RT-114 for obesity expected to start H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":172000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143426,"accession_number":"0001193125-25-159793","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2025-07-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Rani Therapeutics raises $3.0M via stock and warrant offering; suspends ATM facility","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered securities purchase agreement to issue 4.354M shares and 3.146M pre-funded warrants at $0.40/share.","Gross proceeds expected to be ~$3.0M; closing expected on July 16, 2025.","Suspended its Controlled Equity Offering ATM program with H.C. Wainwright.","Directors and officers entered into 45-day lock-up agreements.","Placement agent Maxim Group LLC receives 5.25% cash fee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161607,"accession_number":"0000950170-25-090384","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Rani Therapeutics receives Nasdaq bid price deficiency notice; 180-day cure ends Dec 17","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on June 20, 2025 for non-compliance with $1.00 minimum bid price (30 consecutive business days below $1.00).","Must regain compliance by December 17, 2025 by maintaining a closing bid price of at least $1.00 for 10 consecutive business days.","If not cured, may transfer to Nasdaq Capital Market for an additional 180-day period, subject to meeting other initial listing standards.","Company will monitor bid price and consider options, including a potential reverse stock split.","No assurance that the company will regain compliance or that Nasdaq will grant an extension."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161606,"accession_number":"0000950170-25-078949","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2025-05-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Rani Therapeutics annual meeting elects 7 directors, ratifies auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All seven director nominees (Talat Imran, Mir Imran, Ausiello, Butel, Farquharson, Nanavaty, Rometty) elected; ~229.4M for each.","Ratification of CBIZ CPAs P.C. as auditor for FY2025 passed with ~238.5M for, 417k against, 817k abstain.","Broker non-votes of ~10.0M shares on director elections; no broker non-votes on auditor ratification.","Annual meeting held May 28, 2025; record date April 2, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161605,"accession_number":"0001193125-25-122872","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Rani Therapeutics induces warrant exercise by Armistice, receives ~$4.3M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$4.3M from cash exercise of Series B & C warrants at reduced exercise price of $0.65/sh.","Issues new Series D warrant for 13,160,172 shares at $0.65/sh, 5-year term, subject to stockholder approval.","Company must file resale registration statement for Series D shares within 45 days; seeks Nasdaq approval.","Maxim Group receives 5.25% cash fee on gross proceeds as financial advisor.","Proceeds to be used for working capital and general corporate purposes via Rani LLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161604,"accession_number":"0000950170-25-070344","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rani Therapeutics Q1 net loss $12.7M, cash $15.9M; RT-114 Phase 1 mid-2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss was $12.7M for Q1 2025 ($14.8M in Q1 2024); cash, equivalents and marketable securities fell to $15.9M from $27.6M at year-end.","Preclinical data show RT-114 (oral bispecific GLP-1/GLP-2 agonist) bioequivalent to subcutaneous PG-102 with 111% relative bioavailability.","Preclinical data also demonstrate oral semaglutide via RaniPill (RT-116) comparable to subcutaneous in bioavailability, PK, and weight loss.","Phase 1 clinical trial for RT-114 treating obesity expected to begin mid-2025.","R&D expenses decreased to $6.6M and G&A to $5.6M; contract revenue was $0.2M from evaluation services."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":172000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161603,"accession_number":"0000950170-25-064624","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Rani Therapeutics receives Nasdaq deficiency notice for MVLS below $50M","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Rani on May 1, 2025 that its Market Value of Listed Securities was below $50M for 30 consecutive business days.","Company has 180 calendar days, until October 28, 2025, to regain compliance by achieving MVLS >= $50M for 10 consecutive business days.","If noncompliance persists, Nasdaq may delist; Rani could appeal or apply to transfer to Nasdaq Capital Market.","Rani is considering actions to regain compliance but has not yet decided on a response.","There is no assurance of regaining compliance or meeting other listing criteria."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161602,"accession_number":"0000950170-25-060586","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2025-04-30T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director Laureen DeBuono retires from Rani Therapeutics board; committees reconstituted","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Laureen DeBuono resigned from Board effective April 24, 2025; no disagreement with company.","Board reconstituted Audit Committee: Rometty (Chair), Butel, Nanavaty; Compensation: Nanavaty (Chair), Ausiello.","Nominating and Governance Committee: Butel (Chair), Ausiello, Rometty."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161601,"accession_number":"0000950170-25-052527","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2025-04-09T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Rani Therapeutics auditor Marcum resigns; FY2024 report had going concern note","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Marcum resigned as independent auditor on April 7, 2025; Audit Committee accepted resignation.","FY2024 audit report included explanatory paragraph about substantial doubt regarding going concern.","New auditor CBIZ CPAs P.C. appointed effective April 7, 2025 for fiscal year 2025.","No disagreements or reportable events with Marcum during FY2024 or subsequent interim period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179732,"accession_number":"0000950170-25-047701","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rani Therapeutics reports FY2024 net loss of $56.6M; cash to Q3 2025; RT-114 preclinical data positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2024 net loss of $56.6M vs $67.9M in 2023; cash and marketable securities $27.6M, expected to fund operations into Q3 2025.","Preclinical data for RT-114 (GLP-1/GLP-2 dual agonist) shows 111% relative bioavailability vs subcutaneous, with bioequivalence and comparable weight loss.","Preclinical data for semaglutide oral via RaniPill HC (RT-116) shows bioavailability, PK, and weight loss comparable to subcutaneous.","Phase 1 study of RT-114 for obesity expected to initiate mid-2025; partnership with ProGen for co-development of RT-114.","Impairment loss of $3.7M on construction-in-progress equipment; R&D expenses down $12.9M YoY due to workforce reduction."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":172000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196481,"accession_number":"0000950170-24-126753","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rani Therapeutics Q3 net loss $12.7M; cash $30.4M extended into Q3 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $12.7M for Q3 2024, compared to $18.3M in Q3 2023; includes $4.1M stock-based comp.","Cash, equivalents and marketable securities $30.4M as of Sep 30, 2024; runway extended into Q3 2025.","Completed two equity offerings for total gross proceeds of ~$20.0M in July and October 2024.","New preclinical PK data supports oral delivery of GLP-1/GIP/glucagon triagonist via RaniPill platform.","Phase 1 trial of RT-114 (GLP-1/GLP-2 dual agonist) for obesity expected to start in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196480,"accession_number":"0001193125-24-237838","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2024-10-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Rani Therapeutics to raise ~$10M via stock/warrant offering; cancels prior warrants","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Issuing 3M shares + pre-funded warrants for 333K shares + Series C warrants for 3.33M shares at $3.00 combined price.","Gross proceeds ~$10M; closing expected Oct 16, 2024.","Cancelling Series A warrants for 3.25M shares issued July 2024.","Placement agent Maxim Group LLC receives 5.25% fee.","Directors and officers enter 30-day lock-up."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212792,"accession_number":"0000950170-24-105509","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2024-09-11T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Rani Therapeutics dismisses EY as auditor, appoints Marcum; EY's 2023 report had going concern doubt","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["EY dismissed as independent auditor on Sep 10, 2024; Marcum LLP appointed immediately.","EY's 2023 audit opinion included a going concern explanatory paragraph about substantial doubt.","No disagreements or reportable events in fiscal 2022, 2023, or subsequent interim period.","Letter from EY to SEC confirming agreement attached as Exhibit 16.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212791,"accession_number":"0000950170-24-091744","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rani Therapeutics posts Q2 net loss of $13.4M; announces ProGen partnership for oral obesity drug RT-114","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and marketable securities totaled $30.9M as of June 30, 2024, down from $48.5M at Dec. 31, 2023.","Net loss of $13.4M for Q2 2024, compared to $18.7M in same period 2023; includes $4.1M stock-based compensation.","R&D expenses fell to $6.1M from $11.1M YoY, driven by workforce reduction and timing of preclinical/clinical studies.","Announced co-development partnership with ProGen for RT-114, an oral GLP-1/GLP-2 dual agonist, with 50/50 cost and revenue share.","Phase 1 study for RT-114 expected to start in 2025; completed $10.0M equity offering in July 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212790,"accession_number":"0001193125-24-182549","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2024-07-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Rani Therapeutics raises $10M via registered direct offering with warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$10M from sale of 2.8M shares, 446,753 pre-funded warrants, and warrants for 6.5M shares.","Combined offering price $3.08 per share/warrant unit; warrants exercisable at $3.08 starting six months after closing.","Series A warrants expire 18 months from issuance; Series B warrants expire 5.5 years from issuance.","Directors and officers subject to 60-day lock-up; company restricted from issuing new securities for up to 60 days.","Closing expected July 23, 2024; Maxim Group acted as placement agent with 6% fee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212789,"accession_number":"0000950170-24-083284","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2024-07-12T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Rani Therapeutics decides not to pursue equity financing after investor talks","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Engaged in discussions with investors for a potential equity financing but elected not to proceed.","Decision based on evaluation of business development, cash position, outlook, and market conditions.","Company will continue to assess cash needs and may seek equity financing in the future.","No specific numbers or financial guidance provided in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231836,"accession_number":"0001193125-24-166293","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2024-06-24T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Rani Therapeutics and ProGen partner on GLP-1/GLP-2 dual agonist PG-102 in RaniPill HC for weight management","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Parties will share development costs and operating profits/losses equally; Rani leads US, Canada, Europe, Australia development after Phase 2.","ProGen supplies PG-102; Rani manufactures final Product (Device + compound) worldwide.","Each party can opt-out anytime; continuing party pays low single to mid-single digit royalties on net sales post opt-out.","Priority regulatory markets include US, EU, UK, Canada, Australia, Japan, and South Korea.","Rani leads preclinical through Phase 1 globally; commercial rights split by assigned territories."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231835,"accession_number":"0000950170-24-066552","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2024-05-30T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Rani Therapeutics announces annual meeting results; all director nominees elected","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting held May 29, 2024; all eight director nominees elected with overwhelming support.","Nominees: Talat Imran, Mir Imran, Dennis Ausiello, Jean-Luc Butel, Laureen DeBuono, Andrew Farquharson, Malik Nanavaty, Lisa Rometty.","Ernst & Young ratified as independent auditor for FY2024 with approx. 232M votes for, 16K against.","Class A and Class B shares voted together; Class B shares have ten votes per share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231834,"accession_number":"0000950170-24-053527","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2024-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rani Therapeutics Q1 net loss $14.8M; cash $39.6M; RT-111 Phase 1 positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and marketable securities: $39.6M at March 31, 2024 (down from $48.5M year-end 2023).","Net loss $14.8M for Q1 2024 vs $16.8M same quarter 2023; includes $3.9M stock-based comp.","R&D expense $7.6M (down $2.1M YoY) on lower compensation and third-party costs.","RT-111 (oral anti-IL-12/23 antibody) Phase 1 achieved high bioavailability, well-tolerated, no serious AEs.","Expects Phase 2 trial for RT-102 (osteoporosis) in 2024; RaniPill HC Phase 1 readiness H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":250124,"accession_number":"0000950170-24-034153","cik":1856725,"company_name":"Rani Therapeutics Holdings, Inc.","ticker":"RANI","form_type":"8-K","filed_at":"2024-03-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rani Therapeutics FY2023 net loss $67.9M; cash $48.5M; positive Phase 1 for RT-111 oral antibody","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for FY2023 was $67.9M ($63.3M in 2022); cash and equivalents $48.5M (down from $98.5M at year-end 2022).","Positive topline Phase 1 data for RT-111 (oral anti-IL12/23 antibody): high bioavailability, well-tolerated, no serious adverse events.","Strategic restructuring: discontinued RT-101, paused RT-105/110, reduced workforce, cost savings extend cash runway into 2025.","Phase 2 trial of RT-102 (teriparatide for osteoporosis) to start in 2024; RaniPill HC ready for Phase 1 in H2 2024.","Preclinical data showed transenteric delivery of GLP-1 triagonist elicits rapid weight loss; successful oral delivery of Humira via RaniPill HC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":118184259.4863158,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}